| A multicenter international study of sorafenib treatment in patients with hepatocellular carcinoma and chronic kidney disease undergoing hemodialysis A Diaz-Gonzalez, M Sanduzzi-Zamparelli, LG da Fonseca, ... Journal of Hepatology 70 (1S), E599-E600, 2019 | | 2019 |
| A multidisciplinary approach to peritoneal metastasis from hepatocellular carcinoma: clinical features, management and outcomes L Da Fonseca, P Leonardi, P Hashizume, F Sansone, L Saud, F Carrilho, ... Clinical and experimental hepatology 8 (1), 42-48, 2022 | 4 | 2022 |
| Acquired hemophilia A in a patient with advanced prostate cancer D da Motta Girardi, DRA Silva, PR Villaça, CE Souza, LG da Fonseca, ... Autopsy & Case Reports 5 (2), 55, 2015 | 10 | 2015 |
| Activated lymphocytes and increased risk of dermatologic adverse events during sorafenib therapy for hepatocellular carcinoma J Corominas, V Sapena, M Sanduzzi-Zamparelli, C Millán, E Samper, ... Cancers 13 (3), 426, 2021 | 5 | 2021 |
| Activated lymphocytes and increased risk of dermatologic adverse events during sorafenib therapy for hepatocellular carcinoma. Cancers (Basel). 2021; 13 (3): 426 J Corominas, V Sapena, M Sanduzzi‐Zamparelli, C Millán, E Samper, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | 1 | 2021 |
| Acute acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib LG da Fonseca, R Barroso-Sousa, J Sabbaga, PM Hoff Clinics and Practice 4 (1), 635, 2014 | 19 | 2014 |
| Adherence and quality are key for a beneficial HCC surveillance LGD FONSECA, A Forner Liver International, 2020 | 1 | 2020 |
| An infectious etiology of esophageal cancer spreading from endemic to non-endemic areas LG Fonseca, PH Hashizume ELSEVIER ESPANA SLU, 2021 | 2 | 2021 |
| aspirin and NSAID for chemoprevention of hepatocellular carcinoma—ready for their use? LG Da Fonseca, A Forner Alimentary Pharmacology & Therapeutics 54 (6), 2021 | 5 | 2021 |
| Assessing the impact of COVID-19 on liver cancer management (CERO-19) S Muñoz-Martínez, V Sapena, A Forner, JC Nault, G Sapisochin, ... JHEP reports 3 (3), 100260, 2021 | 51 | 2021 |
| Association between metabolic disorders and cholangiocarcinoma: impact of a postulated risk factor with rising incidence LG Da Fonseca, PH Hashizume, IS de Oliveira, L Izquierdo-Sanchez, ... Cancers 14 (14), 3483, 2022 | 1 | 2022 |
| Atualização das Recomendações da Sociedade Brasileira de Hepatologia para o Tratamento Sistêmico do Carcinoma Hepatocelular AL CHAGAS, CRG LEAL, VB MELLO, FMDR BARROS, ... Arq. gastroenterol, 106-131, 2023 | 1 | 2023 |
| Brazilian Society of Hepatology Updated Recommendations for Systemic Treatment of Hepatocellular Carcinoma AL Chagas, CRG Leal, VB Mello, FMDR Barros, PL Bittencourt, AA Mattos, ... Arquivos de gastroenterologia 60, 106-131, 2023 | | 2023 |
| Can thrombotic events be a major concern in hepatocellular carcinoma patients under systemic treatment during SARS‐Cov‐2? L Fonseca, FJ Carrilho Liver International 40 (12), 2020 | 2 | 2020 |
| Carbon‐ion radiotherapy for HCC—A potential tool to fulfil an unmet gap in the treatment algorithms? LG Da Fonseca, A Forner Liver International 38 (12), 2018 | | 2018 |
| Cardiac angiosarcoma: an unexpected diagnosis MRF Crenitte, MD Galvão, FDC Bernardi, LG da Fonseca Autopsy & Case Reports 4 (3), 53, 2014 | 1 | 2014 |
| Cardiac safety of (neo) adjuvant trastuzumab in the community setting: a single-center experience L Gomes da Fonseca, D de Melo Gagliato, TK Takahashi, M Perez Mak, ... Breast Care 9 (4), 255-260, 2014 | 13 | 2014 |
| Circulating tumor DNA detection in the management of anti-EGFR therapy for advanced colorectal cancer FH Knebel, F Bettoni, LG Da Fonseca, AA Camargo, J Sabbaga, ... Frontiers in Oncology 9, 170, 2019 | 18 | 2019 |
| Circulating tumour DNA sequencing identifies a genetic resistance-gap in colorectal cancers with acquired resistance to EGFR-antibodies and chemotherapy FH Knebel, LJ Barber, A Newey, D Kleftogiannis, A Woolston, B Griffiths, ... Cancers 12 (12), 3736, 2020 | 6 | 2020 |
| Clinical trial identification: NCT01908426 Legal entity responsible for the study: The authors. Funding: Exelixis, Inc. Disclosure: AL. Cheng: Honoraria, Consulting, Advisory … LG Da Fonseca, GN Marta, MI Braghiroli, PM Hoff, J Sabbaga | | |
